Put companies on watchlist
Limes Schlosskliniken AG
ISIN: DE000A0JDBC7
WKN: A0JDBC
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Limes Schlosskliniken AG · ISIN: DE000A0JDBC7 · EQS - adhoc news (20 News)
Country: Germany · Primary market: Germany · EQS NID: 1607125
13 April 2023 01:15PM

Limes Schlosskliniken AG: Audited consolidated financial statements 2022/Approval and adoption of the consolidated financial statements 31.12.2022 of LIMES Schlosskliniken/Outlook 2023


EQS-Ad-hoc: Limes Schlosskliniken AG / Key word(s): Annual Results/Forecast
Limes Schlosskliniken AG: Audited consolidated financial statements 2022/Approval and adoption of the consolidated financial statements 31.12.2022 of LIMES Schlosskliniken/Outlook 2023

13-Apr-2023 / 13:15 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


DGAP-Adhoc: Limes Schlosskliniken AG:

Audited consolidated financial statements 2022 / Approval and adoption of the consolidated financial statements per 31.12.2022 of LIMES Schlosskliniken / Outlook 2023

 

  • Total revenue 30.1 Mio. EUR, (p. y. 25.2 Mio. EUR) + 19,1 %
     
  • Gross earnings (EBITDA) 8,653 kEUR, (p. y.  6,015 kEUR) + 43,9 %
     
  • Operating result (EBIT) 5,998 kEUR, (Vj. 4.530 kEUR) + 32,4 %
     
  • Consolidated net income fort he period 4,864 kEUR, (p. y. 4,109 kEUR) + 18,4 %
     
  • Earnings after minorities and after taxes (EAT) 4,204 kEUR, (p. y. 3,944 kEUR) + 6,6 %
     
  • Earnings per share 14,34 EUR, (p. y. 13,45 EUR)
     
  • Handover of new Lindlar clinic location postponed
     
  • Two more new clinic acquisitions planned for 2023

 

Cologne, April, 13, 2023: At its meeting today, the Supervisory Board of LIMES Schlosskliniken AG approved the consolidated financial statements for 2022, which were audited by the auditing firm
B-S-H Collegen GmbH. Our revenue forecast for 2023 is in excess of EUR 30 million, with EBITDA at roughly the same level as the previous year. We will only be able to pass on the cost increases due to current inflation with a time lag. We have not planned any turnover for the project in Lindlar in 2023. The forecast does not include new acquisitions. We are currently in advanced negotiations for two clinic acquisitions. If these projects materialize, this would add a further EUR 10 million turnover in 2023 and an additional similar amount in 2024.


The LIMES Schlosskliniken Group operates high-quality private clinics in Germany for stress-related illnesses, mental and emotional disorders, such as depression, affective disorders and acute burnout conditions. The range of services is aimed at private patients, those entitled to state aid and self-payers. The LIMES Schlosskliniken Group stands for the special approach of a relationship-oriented medicine in the treatment of people with mental illnesses. In addition to top medical quality, patients are offered a unique, protected and healing environment in which they can recover holistically. Further information is available at www.limes-schlosskliniken.de.

Your contact person:
LIMES Schlosskliniken AG, Petra Kaes, Investor Relations
Kaiser-Wilhelm-Ring 26, 50672 Köln
Tel.: 02203 / 29014-202, p.kaes@limes.care, www.limes-schlosskliniken.de

Language:            English
Company:            LIMES Schlosskliniken AG,   Kaiser-Wilhelm-Ring 26, 50672 Köln, Germany
Phone:                +49 2203 29014-202
Mail:                    p.kaes@limes.care
Internet:               www.limes-schlosskliniken.de
ISIN:                    DE000A0JDBC7
WKN:                  AOJDBC
Stock exchange:  Düsseldorf Freiverkehr, Primärmarkt, XETRA

End of the message



End of Inside Information

13-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Limes Schlosskliniken AG
Kaiser-Wilhelm-Ring 26
50672 Köln
Germany
ISIN: DE000A0JDBC7
WKN: A0JDBC
Listed: Regulated Unofficial Market in Dusseldorf
EQS News ID: 1607125

 
End of Announcement EQS News Service

1607125  13-Apr-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1607125&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Limes Schlosskliniken AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.